Location History:
- Solna, SE (2015)
- Handen, SE (2021)
Company Filing History:
2 out of 2 
1 out of 832,812 Years Active: 2015-2021
Title: Innovations by Vedran Hasimbegovic
Introduction
Vedran Hasimbegovic is a notable inventor based in Solna, Sweden. He has made significant contributions to the field of neuroprotection, particularly in the treatment of parkinsonism. With a total of 3 patents, his work focuses on developing compounds that can aid in the management of various neurodegenerative conditions.
Latest Patents
One of his latest patents is titled "Idoxuridine and its analogs as neuroprotectants for the treatment of parkinsonism." This invention relates to compounds that are beneficial in treating parkinsonism associated with conditions such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, corticobasal degeneration, and progressive supranuclear palsy. The compounds include idoxuridine and its analogs, as well as their metabolic precursors, such as ropidoxuridine. The patent also outlines methods for identifying compounds that can increase the amount of GPR37 in cell membranes, along with methods for the chemical synthesis of ropidoxuridine.
Another significant patent is focused on a thionation process and a thionating agent. This process transforms a group >C=O in a compound into a group >C=S or into a tautomeric form of that group, resulting in a thionated reaction product. The thionating agent used in this process is crystalline PS.2 CHN.
Career Highlights
Throughout his career, Vedran Hasimbegovic has worked with various companies, including Vironova and Thionation AB. His expertise in neuroprotection and chemical synthesis has positioned him as a valuable contributor to the field.
Collaborations
He has collaborated with notable individuals such as Birgitta Pettersson and Per H Svensson, further enhancing the impact of his work in the scientific community.
Conclusion
Vedran Hasimbegovic's innovative contributions to neuroprotection and his patents reflect his commitment to advancing treatments for parkinsonism. His work continues to influence the field and offers hope for improved therapies in the future.